Saline | HDM+LPS | |||
Placebo | rhAPC | Placebo | rhAPC | |
IL-8 pg·mL−1 | 623±222 | 244±75 | 1047±204 | 1513±386** |
IL-1β pg·mL−1 | 3.6±1.5 | 2.1±1.3 | 17.3±5.1*** | 9.0±5.1** |
TNF-α pg·mL−1 | 32.8±19.2 | 5.7±2.7 | 208±82** | 135±35*** |
MIP-1α pg·mL−1 | 46.1±17.0 | 25.9±16.3 | 206.7±54.5*** | 310.9±79.7** |
MIP-1β pg·mL−1 | 920±324 | 459±170 | 2470±174*** | 2081±306** |
C3a pg·mL−1 | 5317±1668 | 3273±1049 | 13 258±2408** | 9343±1736* |
C3bc nM | 3.4±0.16 | 1.4±0.2# | 11.3±2.6** | 5.8±1.3** |
C4bc nM | 0.16±0.04 | 0.06±0.02# | 0.38±0.12* | 0.18±0.03** |
PGE2 pg·mL−1 | 36.2±3.6 | 27.7±1.5 | 47.2±4.3** | 37.9±2.0** |
Data are presented as mean±se of 12 patients. Concentrations in bronchoalveolar lavage fluid of interleukin (IL)-8, IL-1β, tumour necrosis factor (TNF)-α, macrophage inflammatory protein (MIP)-1α, MIP-1β, C3a, C3bc, C4bc and prostaglandin (PG)E2. *: p<0.05 versus control; **: p<0.01 versus control; ***: p<0.001 versus control; #: p<0.05 versus placebo.